COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,388 Articles (22,816 medRxiv, 8,572 bioRxiv)

Most recent first Previous |  Page 1949: Articles 19481-19490  | Next

Characterization of cell-cell communication in COVID-19 patients
Lin, Y., Loo, L., Tran, A., Moreno, C., Hesselson, D., Neely, G. G., Yang, J. Y. H.
10.1101/2020.12.30.424641 — Posted: 2020-12-30
Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2
Biering, S. B., Van Dis, E., Wehri, E., Yamashiro, L. H., Nguyenla, X., Dugast-Darzacq, C., Graham, T. G., Stroumza, J. R., Golovkine, G. R., Roberts, A. W., Fines, D. M., Spradlin, J. N., Ward, C. C., Bajaj, T., Dovala, D., Gahmen, U. S., Bajaj, R., Fox, D. M., Ott, M., Murthy, N., Nomura, D., Schaletzky, J., Stanley, S. A.
10.1101/2020.12.30.424862 — Posted: 2020-12-30
A novel fermented Yi traditional medicine efficiently suppresses the replication of SARS-CoV-2 in vitro
Fang, S., Xu, B., Song, X., Xie, Y., Yang, X.
10.1101/2020.12.29.424534 — Posted: 2020-12-30
Engineering, production and characterization of Spike and Nucleocapsid structural proteins of SARS-CoV-2 in Nicotiana benthamiana as vaccine candidates against COVID-19
Mammedov, T., Yuksel, D., Ilgin, M., Gurbuzaslan, I., Gulec, B., Mammadova, G., Say, D., Hasanova, G.
10.1101/2020.12.29.424779 — Posted: 2020-12-30
Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro
Woo, H. G., Shah, M., Moon, S. U.
10.1101/2020.12.30.424801 — Posted: 2020-12-30
In vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19
Santoso, C. S., Li, Z., Rottenberg, J. T., Liu, X., Shen, V. X., Fuxman Bass, J. I.
10.1101/2020.12.29.424728 — Posted: 2020-12-30
Meta-analysis of virus-induced host gene expression reveals unique signatures of immune dysregulation induced by SARS-CoV-2
Kuchi, S., Gu, Q., Palmarini, M., Wilson, S. J., Robertson, D. L.
10.1101/2020.12.29.424739 — Posted: 2020-12-30
An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro
Yang, X., Liu, L., Hao, Y., So, Y. W., Emami, S. S., Zhang, D., Gong, Y., Sheth, P., Wang, Y.
10.1101/2020.12.29.424698 — Posted: 2020-12-29
Lentiviral vector-based SARS-CoV-2 pseudovirus enables analysis of neutralizing activity in COVID-19 convalescent plasma
Pamukcu, C., Celik, E., Ergun, E. Z., Karahan, Z. S., Turkoz, G., Aras, M., Eren, C., Sili, U., Bilginer, H., Suder, I., Mandaci, B. C., Dingiloglu, B., Tatli, O., Dinler Doganay, G., Baris, S., Ozoren, N., Sutlu, T.
10.1101/2020.12.28.424590 — Posted: 2020-12-29
Structural dynamics of the SARS-CoV-2 frameshift-stimulatory pseudoknot reveal topologically distinct conformers
Neupane, K., Zhao, M., Lyons, A., Munshi, S., Ileperuma, S. M., Ritchie, D. B., Hoffer, N. Q., Narayan, A., Woodside, M. T.
10.1101/2020.12.28.424630 — Posted: 2020-12-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).